Member-only story
A-List Offers Patient and Caregiver Insights into Dementia By
As we grapple with the scientific challenges of discovering therapies to prevent or slow Alzheimer’s disease, we are faced with other, related challenges. How do the physiological hallmarks of the disease — like the buildup of the proteins beta-amyloid and tau — influence the lived experience? Are there experiential features of the disease for which we have not identified biomarkers? Why are the brains of distinct demographic groups differentially affected by Alzheimer’s disease, and what are the implications for treatment and care?
UsAgainstAlzheimer’s has launched and incubated an extensive suite of initiatives that include traditional approaches to Alzheimer’s disease that promote basic, clinical, and translational research to broaden our understanding of disease mechanisms and how therapeutic agents can be used to intervene in disease processes. However, other initiatives allow the organization to more directly engage families wrestling with all stages of Alzheimer’s disease and each of its complex components. The goal with these latter efforts is to improve quality of life for those with Alzheimer’s disease and their families while science pursues breakthroughs to prevent or slow the disease itself. The foundational assets UsAgainstAlzheimer’s is building as part of these programs…
